Advanced search
Publication Cover
Molecular and Cellular Biology Volume 28, 2008 - Issue 3
Submit an article Journal homepage
152
Views
263
CrossRef citations to date
0
Altmetric
Article

Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression

Zhiyuan YangDepartment of Molecular and Cell Biology, University of California, Berkeley, California94720
,
Nanhai HeDepartment of Molecular and Cell Biology, University of California, Berkeley, California94720
&
Qiang ZhouDepartment of Molecular and Cell Biology, University of California, Berkeley, California94720Correspondence[email protected]
Pages 967-976 | Received 10 Jun 2007, Accepted 09 Nov 2007, Published online: 27 Mar 2023

Citations (263)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (13)

Haiyu Niu, Feixue Song, Hanwen Wei, Yuan Li, Hao Huang & Changping Wu. (2021) Inhibition of BRD4 Suppresses the Growth of Esophageal Squamous Cell Carcinoma. Cancer Investigation 39:10, pages 826-841.
Read now
S.L. Wu, L.F. Wang, H.B. Sun, W. Wang & Y.X. Yu. (2020) Probing molecular mechanism of inhibitor bindings to bromodomain-containing protein 4 based on molecular dynamics simulations and principal component analysis. SAR and QSAR in Environmental Research 31:7, pages 547-570.
Read now
Montserrat Pérez-Salvia & Manel Esteller. (2017) Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics 12:5, pages 323-339.
Read now
Christian J. Braun & Michael T. Hemann. (2016) Rewiring the solid tumor epigenome for cancer therapy. Expert Review of Anticancer Therapy 16:9, pages 977-987.
Read now
Ryan P. McNamara, Curtis W. Bacon & Iván D'Orso. (2016) Transcription elongation control by the 7SK snRNP complex: Releasing the pause. Cell Cycle 15:16, pages 2115-2123.
Read now
Jessica M. Bryant, Greg Donahue, Xiaoshi Wang, Mirella Meyer-Ficca, Lacey J. Luense, Angela H. Weller, Marisa S. Bartolomei, Gerd A. Blobel, Ralph G. Meyer, Benjamin A. Garcia & Shelley L. Berger. (2015) Characterization of BRD4 during Mammalian Postmeiotic Sperm Development. Molecular and Cellular Biology 35:8, pages 1433-1448.
Read now
Ramon M Rodriguez, Beatriz Suarez-Alvarez, Ruben Salvanés, Covadonga Huidobro, Estela G Toraño, Jose L Garcia-Perez, Carlos Lopez-Larrea, Agustin F Fernandez, Clara Bueno, Pablo Menendez & Mario F Fraga. (2014) Role of BRD4 in hematopoietic differentiation of embryonic stem cells. Epigenetics 9:4, pages 566-578.
Read now
Allen S Ho, Sevin Turcan & Timothy A Chan. (2013) Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. OncoTargets and Therapy 6, pages 223-232.
Read now
Ballachanda N. Devaiah & Dinah S. Singer. (2013) Two faces of BRD4. Transcription 4:1, pages 13-17.
Read now
Stephan Kadauke & Gerd A. Blobel. (2012) “Remembering” tissue-specific transcription patterns through mitosis. Cell Cycle 11:21, pages 3911-3912.
Read now
Tom D Heightman. (2011) Therapeutic prospects for epigenetic modulation. Expert Opinion on Therapeutic Targets 15:6, pages 729-740.
Read now
Alexey S. Revenko, Ekaterina V. Kalashnikova, Abigael T. Gemo, June X. Zou & Hong-Wu Chen. (2010) Chromatin Loading of E2F-MLL Complex by Cancer-Associated Coregulator ANCCA via Reading a Specific Histone Mark. Molecular and Cellular Biology 30:22, pages 5260-5272.
Read now
Jianxin You, Qing Li, Chong Wu, Jina Kim, Matthias Ottinger & Peter M. Howley. (2009) Regulation of Aurora B Expression by the Bromodomain Protein Brd4. Molecular and Cellular Biology 29:18, pages 5094-5103.
Read now

Articles from other publishers (250)

Bharath Kumar Gajjela & Ming-Ming Zhou. (2023) Bromodomain inhibitors and therapeutic applications. Current Opinion in Chemical Biology 75, pages 102323.
Crossref
Shahrzad S. Fard, Shaghayegh Kouchaki, Zahra Salimian, Masoud Sotoudeh, Seyed A. Mousavi, Kamran Alimoghaddam & Seyed H. Ghaffari. (2023) Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry 23:7, pages 794-806.
Crossref
Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernández-Guerrero, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, Barbara Amoroso, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Xin Wei, Zariana Nikolova & Irene Braña. (2023) BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nature Communications 14:1.
Crossref
Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer & Michael Dickinson. (2023) A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research 29:4, pages 711-722.
Crossref
Koh Fujinaga, Fang Huang & B. Matija Peterlin. (2023) P-TEFb: The master regulator of transcription elongation. Molecular Cell 83:3, pages 393-403.
Crossref
Pan Zhang, Yongchuang Li, Duwei Zheng, Songsong Hua, Chongyang Song, Zhengmin Li, Tingting Shi, Panpan Wang, Binlun Yan, Jitao Li & Huan Gao. (2022) Cloning and function of the cyclin‐dependent kinase 9 gene in ovarian development of the ridgetail white prawn, Exopalaemon carinicauda . Aquaculture Research 53:17, pages 6029-6038.
Crossref
Yongfeng Tao, David Remillard, Ekaterina V. Vinogradova, Minoru Yokoyama, Sofia Banchenko, David Schwefel, Bruno Melillo, Stuart L. Schreiber, Xiaoyu Zhang & Benjamin F. Cravatt. (2022) Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1. Journal of the American Chemical Society 144:40, pages 18688-18699.
Crossref
Naidi Yang, Dipanwita Das, Shilpa Rani Shankar, Pierre-Alexis Goy, Ernesto Guccione & Reshma Taneja. (2022) An interplay between BRD4 and G9a regulates skeletal myogenesis. Frontiers in Cell and Developmental Biology 10.
Crossref
Jiacheng Li, Ting Liu, Yuanli Song, Mingyu Wang, Liping Liu, Hongwen Zhu, Qi Li, Jin Lin, Hualiang Jiang, Kaixian Chen, Kehao Zhao, Mingliang Wang, Hu Zhou, Hua Lin & Cheng Luo. (2022) Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer. Journal of Medicinal Chemistry 65:16, pages 11034-11057.
Crossref
Hussain Elhasasna, Raymond Khan, Kalpana K. Bhanumathy, Frederick S. Vizeacoumar, Prachi Walke, Maricris Bautista, Dinesh K. Dahiya, Vincent Maranda, Hardikkumar Patel, Amrutha Balagopal, Nezeka Alli, Anand Krishnan, Andrew Freywald & Franco J. Vizeacoumar. (2022) A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers. Cells 11:14, pages 2246.
Crossref
Pallav Sengupta, Hira Choudhury, Sulagna Dutta, Shery Jacob, Prashant Kesharwani & Bapi Gorain. (2022) Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine. Particle & Particle Systems Characterization 39:7, pages 2100276.
Crossref
Mehdi Sharifi Tabar, Habib Francis, Dannel Yeo, Charles G. Bailey & John E. J. Rasko. (2022) Mapping oncogenic protein interactions for precision medicine. International Journal of Cancer 151:1, pages 7-19.
Crossref
Xiang Ling, Wenjie Wu, Ieman A. M. Aljahdali, Jianqun Liao, Sreevidya Santha, Christos Fountzilas, Patrick M. Boland & Fengzhi Li. (2022) FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clinical and Translational Medicine 12:5.
Crossref
Florian Stieglitz, Ralf Gerhard, Rabea Hönig, Klaudia Giehl & Andreas Pich. (2022) TcdB of Clostridioides difficile Mediates RAS-Dependent Necrosis in Epithelial Cells. International Journal of Molecular Sciences 23:8, pages 4258.
Crossref
Siyi Zhang, Ping Bai, Dan Lei, Yingxia Liang, Sherri Zhen, Grisilda Bakiasi, Hao Pang, Se Hoon Choi, Changning Wang, Rudolph E. Tanzi & Can Zhang. (2022) Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer’s disease-related neuropathology in cell models. Journal of Biological Chemistry 298:4, pages 101794.
Crossref
Lauriane Lemelle, Antoine Moya-Plana, Benoît Dumont, Brice Fresneau, Anne Laprie, Line Claude, Sophie Deneuve, Camille Cordero, Gaelle Pierron, Vincent Couloigner, Sophie Bernard, Liesbeth Cardoen, Hervé J. Brisse, Nina Jehanno, Lucy Metayer, Paul Fréneaux, Sylvie Helfre, Fréderic Kolb, Juliette Thariat, Yves Réguerre & Daniel Orbach. (2022) NUT carcinoma in children, adolescents and young adults. Bulletin du Cancer 109:4, pages 491-504.
Crossref
Hafiz Akbar Ali, Yalan Li, Akram Hafiz Muhammad Bilal, Tingting Qin, Ziqiao Yuan & Wen Zhao. (2022) A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles. Frontiers in Pharmacology 13.
Crossref
Vanessa Moreno, Karan Saluja & Sergio Pina-Oviedo. (2022) NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics. Frontiers in Oncology 12.
Crossref
Sophie Cousin, Jean‐Yves Blay, Irene Braña Garcia, Johann S. Bono, Christophe Le Tourneau, Victor Moreno, Jose Trigo, Christine L. Hann, Arun A. Azad, Seock‐Ah Im, Philippe A. Cassier, Christopher A. French, Antoine Italiano, Vicki L. Keedy, Ruth Plummer, Marie‐Paule Sablin, Matthew L. Hemming, Geraldine Ferron‐Brady, Anastasia Wyce, Ahmed Khaled, Antara Datta, Shawn W. Foley, Michael T. McCabe, Yuehui Wu, Thierry Horner, Brandon E. Kremer, Arindam Dhar, Peter J. O'Dwyer, Geoffrey I. Shapiro & Sarina A. Piha‐Paul. (2021) Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I / II open‐label, dose escalation study . International Journal of Cancer 150:6, pages 993-1006.
Crossref
Liyun Miao, Yin Tang, Ashley R. Bonneau, Shun Hang Chan, Mina L. Kojima, Mark E. Pownall, Charles E. Vejnar, Feng Gao, Smita Krishnaswamy, Caroline E. Hendry & Antonio J. Giraldez. (2022) The landscape of pioneer factor activity reveals the mechanisms of chromatin reprogramming and genome activation. Molecular Cell 82:5, pages 986-1002.e9.
Crossref
Wenhua Jiang, Xiaohui Wang, Chengxia Shu, Qiangqiang Hou, Kexin Yang & Xiaoxing Wu. (2022) Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer. Bioorganic Chemistry 119, pages 105575.
Crossref
Kai Zhou, Songkuan Zhuang, Fulong Liu, Yanheng Chen, You Li, Shihui Wang, Yuxuan Li, Huixin Wen, Xiaohua Lin, Jie Wang, Yue Huang, Cailing He, Nan Xu, Zongshu Li, Lang Xu, Zixuan Zhang, Lin-Feng Chen, Ruichuan Chen & Min Liu. (2022) Disrupting the Cdk9/Cyclin T1 heterodimer of 7SK snRNP for the Brd4 and AFF1/4 guided reconstitution of active P-TEFb. Nucleic Acids Research 50:2, pages 750-762.
Crossref
Mohammed El Dika, Andrew J. Fritz, Rabail H. Toor, Princess D. Rodriguez, Stephen J. Foley, Rahim Ullah, Daijing Nie, Bodhisattwa Banerjee, Dorcas Lohese, Kirsten M. Tracy, Karen C. Glass, Seth Frietze, Prachi N. Ghule, Jessica L. Heath, Anthony N. Imbalzano, Andre van Wijnen, Jonathan Gordon, Jane B. Lian, Janet L. Stein & Gary S. Stein. 2022. Nuclear, Chromosomal, and Genomic Architecture in Biology and Medicine. Nuclear, Chromosomal, and Genomic Architecture in Biology and Medicine 375 396 .
Janina Schreiber, Nastassia Liaukouskaya, Lars Fuhrmann, Alexander-Thomas Hauser, Manfred Jung, Tobias B. Huber & Nicola Wanner. (2021) BET Proteins Regulate Expression of Osr1 in Early Kidney Development. Biomedicines 9:12, pages 1878.
Crossref
Ana Luiza Drumond-Bock & Magdalena Bieniasz. (2021) The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. Molecular Cancer 20:1.
Crossref
Hitoshi Shiota, Artyom A. Alekseyenko, Zhipeng A. Wang, Ivona Filic, Tatiana M. Knox, Nhi M. Luong, Yeying Huang, David A. Scott, Kristen L. Jones, Prafulla C. Gokhale, Madeleine E. Lemieux, Philip A. Cole, Mitzi I. Kuroda & Christopher A. French. (2021) Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment. Molecular Cancer Research 19:11, pages 1818-1830.
Crossref
Abigail E. Burgess, Torsten Kleffmann & Peter D. Mace. (2021) Oncogenic Truncations of ASXL1 Enhance a Motif for BRD4 ET-Domain Binding. Journal of Molecular Biology 433:22, pages 167242.
Crossref
Carlos Perea-Resa, Lauren Wattendorf, Sammer Marzouk & Michael D. Blower. (2021) Cohesin: behind dynamic genome topology and gene expression reprogramming. Trends in Cell Biology 31:9, pages 760-773.
Crossref
Jaya Padmanabhan, Biswarup Saha, Chase Powell, Qianxing Mo, Bradford A. Perez & Srikumar Chellappan. (2021) Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers 13:15, pages 3906.
Crossref
Nieves Lara-Ureña & Mario García-Domínguez. (2021) Relevance of BET Family Proteins in SARS-CoV-2 Infection. Biomolecules 11:8, pages 1126.
Crossref
Pablo García-Gutiérrez & Mario García-Domínguez. (2021) BETting on a Transcriptional Deficit as the Main Cause for Cornelia de Lange Syndrome. Frontiers in Molecular Biosciences 8.
Crossref
Gabriel Prado, Charlotte L. Kaestner, Jonathan D. Licht & Richard L. Bennett. (2021) Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1868:8, pages 119047.
Crossref
Anu Shilpa Krishnatry, Alexander Voelkner, Arindam Dhar, Marita Prohn & Geraldine Ferron‐Brady. (2021) Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model. CPT: Pharmacometrics & Systems Pharmacology 10:7, pages 709-722.
Crossref
Harpreet K Mandhair, Urban Novak & Ramin Radpour. (2021) Epigenetic regulation of autophagy: A key modification in cancer cells and cancer stem cells. World Journal of Stem Cells 13:6, pages 542-567.
Crossref
Esin Orhan, Carolina Velazquez, Imene Tabet, Claude Sardet & Charles Theillet. (2021) Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?. Cancers 13:12, pages 2930.
Crossref
Zlata Vershinin, Michal FeldmanThilo Werner, Lital Estrella Weil, Margarita Kublanovsky, Elina Abaev-SchneidermanMenachem SklarzEnid Y. N. Lam, Khawla Alasad, Sarah Picaud, Barak Rotblat, Ruth A. McAdamVered Chalifa-Caspi, Marcus Bantscheff, Trevor ChapmanHuw D. LewisPanagis Filippakopoulos, Mark A. Dawson, Paola Grandi, Rab K. Prinjha & Dan Levy. (2021) BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation. Science Advances 7:22.
Crossref
Abel Tesfaye Anshabo, Robert Milne, Shudong Wang & Hugo Albrecht. (2021) CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Frontiers in Oncology 11.
Crossref
Zheng Zhang, Xiaolan Xing, Peng Guan, Shubin Song, Guirong You, Chengcai Xia & Tingting Liu. (2021) Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies. European Journal of Medicinal Chemistry 217, pages 113314.
Crossref
Tatiana Shorstova, William D. Foulkes & Michael Witcher. (2021) Achieving clinical success with BET inhibitors as anti-cancer agents. British Journal of Cancer 124:9, pages 1478-1490.
Crossref
Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori & Christopher J. Kemp. (2021) Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Molecular Cancer Therapeutics 20:4, pages 691-703.
Crossref
Shiliang Wu, Lifei Wang, Lulu Zhang, Xiaoyan Xu & Juan Zhao. (2021) Molecular dynamics insights into binding selectivity of inhibitors toward BRD4 and CBP. Chemical Physics Letters 769, pages 138435.
Crossref
Kyle P. Eagen & Christopher A. French. (2021) Supercharging BRD4 with NUT in carcinoma. Oncogene 40:8, pages 1396-1408.
Crossref
Jochen Dutzmann, Marco Haertlé, Jan-Marcus Daniel, Frederik Kloss, Robert-Jonathan Musmann, Katrin Kalies, Kai Knöpp, Claudia Pilowski, Mirja Sirisko, Jan-Thorben Sieweke, Johann Bauersachs, Daniel G Sedding & Simona Gegel. (2021) BET bromodomain-containing epigenetic reader proteins regulate vascular smooth muscle cell proliferation and neointima formation. Cardiovascular Research 117:3, pages 850-862.
Crossref
Ruochen Liu, Pengfei Shi, Zhongze Wang, Chaoyu Yuan & Hongjuan Cui. (2021) Molecular Mechanisms of MYCN Dysregulation in Cancers. Frontiers in Oncology 10.
Crossref
Katie R. Ryan, Francis Giles & Gareth J. Morgan. (2020) Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma. European Journal of Haematology 106:1, pages 90-99.
Crossref
Mohd. Muddassir, Kunjal Soni, Chetan B. Sangani, Abdullah Alarifi, Mohd. Afzal, Naaser A. Y. Abduh, Yongtao Duan & Poonam Bhadja. (2021) Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs. RSC Advances 11:2, pages 612-636.
Crossref
Yawei Song, Gongcheng Hu, Jinping Jia, Mingze Yao, Xiaoshan Wang, Wenliang Lu, Andrew P. Hutchins, Jiekai Chen, Keiko Ozato & Hongjie Yao. (2020) DNA Damage Induces Dynamic Associations of BRD4/P-TEFb With Chromatin and Modulates Gene Transcription in a BRD4-Dependent and -Independent Manner. Frontiers in Molecular Biosciences 7.
Crossref
Verona Buocikova, Ivan Rios-Mondragon, Eleftherios Pilalis, Aristotelis Chatziioannou, Svetlana Miklikova, Michal Mego, Karlis Pajuste, Martins Rucins, Naouale El Yamani, Eleonora Marta Longhin, Arkadij Sobolev, Muriel Freixanet, Victor Puntes, Aiva Plotniece, Maria Dusinska, Mihaela Roxana Cimpan, Alena Gabelova & Bozena Smolkova. (2020) Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives. Cancers 12:12, pages 3622.
Crossref
Bobbie Pelham-Webb, Dylan Murphy & Effie Apostolou. (2020) Dynamic 3D Chromatin Reorganization during Establishment and Maintenance of Pluripotency. Stem Cell Reports 15:6, pages 1176-1195.
Crossref
Yuan Gao, Hang Zhang, Frédéric Lirussi, Carmen Garrido, Xiang-Yang Ye & Tian Xie. (2020) Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. Biochemical Pharmacology 182, pages 114224.
Crossref
Yao Li, Jie Xiang, Jing Zhang, Jiahao Lin, Yaosen Wu & Xiangyang Wang. (2020) Inhibition of Brd4 by JQ1 Promotes Functional Recovery From Spinal Cord Injury by Activating Autophagy. Frontiers in Cellular Neuroscience 14.
Crossref
Jianwei Chen, Panqiao Zhang, Xinyi Ye, Bin Wei, Mahmoud Emam, Huawei Zhang & Hong Wang. (2020) The Structural Diversity of Marine Microbial Secondary Metabolites Based on Co-Culture Strategy: 2009–2019. Marine Drugs 18:9, pages 449.
Crossref
Qiao Liu, Michelle Garcia, Shaoyuan Wang & Chun-Wei Chen. (2020) Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia. Cells 9:8, pages 1888.
Crossref
Subham Basu, Arijit Nandy & Debabrata Biswas. (2020) Keeping RNA polymerase II on the run: Functions of MLL fusion partners in transcriptional regulation. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1863:8, pages 194563.
Crossref
Ranran Wang, June F. Yang, Flora Ho, Erle S. Robertson & Jianxin You. (2020) Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis. Cancers 12:6, pages 1637.
Crossref
Shwu-Yuan Wu, Chien-Fei Lee, Hsien-Tsung Lai, Cheng-Tai Yu, Ji-Eun Lee, Hao Zuo, Sophia Y. Tsai, Ming-Jer Tsai, Kai Ge, Yihong Wan & Cheng-Ming Chiang. (2020) Opposing Functions of BRD4 Isoforms in Breast Cancer. Molecular Cell 78:6, pages 1114-1132.e10.
Crossref
Mohammadali Soleimani Damaneh, Jian-Ping Hu, Xia-Juan Huan, Shan-Shan Song, Chang-Qing Tian, Dan-Qi Chen, Tao Meng, Yue-Lei Chen, Jing-Kang Shen, Bing Xiong, Ze-Hong Miao & Ying-Qing Wang. (2019) A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. Investigational New Drugs 38:3, pages 700-713.
Crossref
Zizhou Li, Senhao Xiao, Yaxi Yang, Chao Chen, Tian Lu, Zhifeng Chen, Hualiang Jiang, Shijie Chen, Cheng Luo & Bing Zhou. (2020) Discovery of 8-Methyl-pyrrolo[1,2- a ]pyrazin-1(2 H )-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors . Journal of Medicinal Chemistry 63:8, pages 3956-3975.
Crossref
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Phillippe A Cassier, Victor Moreno, Johann S de Bono, Sara Duckworth Harward, Geraldine Ferron-Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J Parr, Rabinder K Prinjha, Christopher L Carpenter, John Hilton, David S Hong, Naomi B Haas, Mark C Markowski, Arindam Dhar, Peter J O’Dwyer & Geoffrey I Shapiro. (2020) Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum 4:2.
Crossref
Oliver Bechter & Patrick Schöffski. (2020) Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors. Pharmacology & Therapeutics 208, pages 107479.
Crossref
Schuyler Lee, Haolin Liu, Ryan Hill, Chunjing Chen, Xia Hong, Fran Crawford, Molly Kingsley, Qianqian Zhang, Xinjian Liu, Zhongzhou Chen, Andreas Lengeling, Kathrin Maria Bernt, Philippa Marrack, John Kappler, Qiang Zhou, Chuan-Yuan Li, Yuhua Xue, Kirk Hansen & Gongyi Zhang. (2020) JMJD6 cleaves MePCE to release positive transcription elongation factor b (P-TEFb) in higher eukaryotes. eLife 9.
Crossref
Natalie Timme, Youjia Han, Shuai Liu, Hailemichael O. Yosief, Heathcliff Dorado García, Yi Bei, Filippos Klironomos, Ian C. MacArthur, Annabell Szymansky, Jennifer von Stebut, Victor Bardinet, Constantin Dohna, Annette Künkele, Jana Rolff, Patrick Hundsdörfer, Andrej Lissat, Georg Seifert, Angelika Eggert, Johannes H. Schulte, Wei Zhang & Anton G. Henssen. (2020) Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. Translational Oncology 13:2, pages 221-232.
Crossref
Fang Tai, Kunxiang Gong, Kai Song, Yanling He & Jian Shi. (2020) Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance. Nature Communications 11:1.
Crossref
Jared P. Taylor, Lucas H. Armitage, Daniel L. Aldridge, Melanie N. Cash & Mark A. Wallet. (2020) Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. Biology Open.
Crossref
Qian W. Huang, Li J. He, Shuang Zheng, Tao Liu & Bei N. Peng. (2019) An Overview of Molecular Mechanism, Clinicopathological Factors, and Treatment in NUT Carcinoma. BioMed Research International 2019, pages 1-6.
Crossref
Reyes-Garau, Ribeiro & Roué. (2019) Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications. Cancers 11:10, pages 1483.
Crossref
Brittany L. Allen-Petersen & Rosalie C. Sears. (2019) Mission Possible: Advances in MYC Therapeutic Targeting in Cancer. BioDrugs 33:5, pages 539-553.
Crossref
Jianping Hu, Chang-Qing Tian, Mohammadali Soleimani Damaneh, Yanlian Li, Danyan Cao, Kaikai Lv, Ting Yu, Tao Meng, Danqi Chen, Xin Wang, Lin Chen, Jian Li, Shan-Shan Song, Xia-Juan Huan, Lihuai Qin, Jingkang Shen, Ying-Qing Wang, Ze-Hong Miao & Bing Xiong. (2019) Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. Journal of Medicinal Chemistry 62:18, pages 8642-8663.
Crossref
Noelia Luna-Peláez, Rosana March-Díaz, María Ceballos-Chávez, Jose A. Guerrero-Martínez, Paolo Grazioli, Pablo García-Gutiérrez, Thomas Vaccari, Valentina Massa, Jose C. Reyes & Mario García-Domínguez. (2019) The Cornelia de Lange Syndrome-associated factor NIPBL interacts with BRD4 ET domain for transcription control of a common set of genes. Cell Death & Disease 10:8.
Crossref
Veronika A. Myasoedova, Vasily Sukhorukov, Andrey V. Grechko, Dongwei Zhang, Elena Romanenko, Vawain Orekhov & Alexander N. Orekhov. (2019) Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. Current Pharmaceutical Design 25:6, pages 635-641.
Crossref
Pan Chen, Yifei Yang, Lingyun Yang, Jiping Tian, Fangqing Zhang, Jinpei Zhou & Huibin Zhang. (2019) 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed C H activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells. Bioorganic Chemistry 86, pages 119-125.
Crossref
Vivek Behera, Aaron J. Stonestrom, Nicole Hamagami, Chris C. Hsiung, Cheryl A. Keller, Belinda Giardine, Simone Sidoli, Zuo-Fei Yuan, Natarajan V. Bhanu, Michael T. Werner, Hongxin Wang, Benjamin A. Garcia, Ross C. Hardison & Gerd A. Blobel. (2019) Interrogating Histone Acetylation and BRD4 as Mitotic Bookmarks of Transcription. Cell Reports 27:2, pages 400-415.e5.
Crossref
Gloria Manzotti, Alessia Ciarrocchi & Valentina Sancisi. (2019) Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Cancers 11:3, pages 304.
Crossref
Youjia Han, Sven Lindner, Yi Bei, Heathcliff Dorado Garcia, Natalie Timme, Kristina Althoff, Andrea Odersky, Alexander Schramm, Andrej Lissat, Annette Künkele, Hedwig E. Deubzer, Angelika Eggert, Johannes H. Schulte & Anton G. Henssen. (2019) Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Cancer Letters 445, pages 24-33.
Crossref
Alexandra Schutkowski, Diana Kalbas, Ulf Reimer & Mike Schutkowski. 2019. Epigenetic Drug Discovery. Epigenetic Drug Discovery 107 132 .
Alejandro Villar-Prados, Sherry Y. Wu, Karem A. Court, Shaolin Ma, Christopher LaFargue, Mamur A. Chowdhury, Margaret I. Engelhardt, Cristina Ivan, Prahlad T. Ram, Ying Wang, Keith Baggerly, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Shyh-Ming Yang, David J. Maloney, Makoto Yoshioka, Jeffrey W. Strovel, Jason Roszik & Anil K. Sood. (2019) Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Molecular Cancer Therapeutics 18:2, pages 421-436.
Crossref
Matthew C. Stubbs, Timothy C. Burn, Richard Sparks, Thomas Maduskuie, Sharon Diamond, Mark Rupar, Xiaoming Wen, Alla Volgina, Nina Zolotarjova, Paul Waeltz, Margaret Favata, Ravi Jalluri, Huiqing Liu, Xuesong Mike Liu, Jun Li, Robert Collins, Nikoo Falahatpisheh, Padmaja Polam, Darlise DiMatteo, Patricia Feldman, Valerie Dostalik, Pramod Thekkat, Christine Gardiner, Xin He, Yanlong Li, Maryanne Covington, Richard Wynn, Bruce Ruggeri, Swamy Yeleswaram, Chu-Biao Xue, Wenqing Yao, Andrew P. Combs, Reid Huber, Gregory Hollis, Peggy Scherle & Phillip C.C. Liu. (2019) The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clinical Cancer Research 25:1, pages 300-311.
Crossref
Tomomi Noguchi-Yachide. 2019. Pharmacoepigenetics. Pharmacoepigenetics 463 473 .
Benedetta Donati, Eugenia Lorenzini & Alessia Ciarrocchi. (2018) BRD4 and Cancer: going beyond transcriptional regulation. Molecular Cancer 17:1.
Crossref
Qun Luo, Wanglong Deng, Haiwei Wang, Huiyong Fan & Ji Zhang. (2018) BRD4 interacts with PML/RARα in acute promyelocytic leukemia. Frontiers of Medicine 12:6, pages 726-734.
Crossref
Wei Chen, Hao Zhang, Zhifeng Chen, Hao Jiang, Liping Liao, Shijie Fan, Jing Xing, Yiqian Xie, Shijie Chen, Hong Ding, Kaixian Chen, Hualiang Jiang, Cheng Luo, Mingyue Zheng, Zhiyi Yao, Yiran Huang & Yuanyuan Zhang. (2018) Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma. Oncogenesis 7:11.
Crossref
Christopher A. French. (2018) NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment. Pathology International 68:11, pages 583-595.
Crossref
Panagis Filippakopoulos. (2018) What Is the BET on Solid Tumors?. Journal of Clinical Oncology 36:30, pages 3040-3042.
Crossref
Alessandro Furlan, Florence Agbazahou, Mélanie Henry, Mariano Gonzalez-Pisfil, Corentin Le Nézet, Dorian Champelovier, Marie Fournier, Bernard Vandenbunder, Gabriel Bidaux & Laurent Héliot. (2018) P-TEFb et Brd4. médecine/sciences 34:8-9, pages 685-692.
Crossref
Guillaume P Andrieu, Jordan S Shafran, Jude T Deeney, Kishan R Bharadwaj, Annapoorni Rangarajan & Gerald V Denis. (2018) BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. Journal of Leukocyte Biology 104:2, pages 265-274.
Crossref
Jingwen Zhang, Austin M. Dulak, Maureen M. Hattersley, Brandon S. Willis, Jenni Nikkilä, Anderson Wang, Alan Lau, Corinne Reimer, Michael Zinda, Stephen E. Fawell, Gordon B. Mills & Huawei Chen. (2018) BRD4 facilitates replication stress-induced DNA damage response. Oncogene 37:28, pages 3763-3777.
Crossref
Yonghui Wang, Wei Wang & Hongqin Sun. (2018) Bromodomain‑containing protein�4 is critical for the antiproliferative and pro‑apoptotic effects of gambogic acid in anaplastic thyroid cancer. International Journal of Molecular Medicine.
Crossref
Hatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, Zachary A. Hing, James S. Blachly, Bonnie Harrington, Shaneice Mitchell, Nicole R. Grieselhuber, Katie Williams, Tzung-Huei Lai, Lapo Alinari, Robert A. Baiocchi, Lindsey Brinton, Elizabeth Baskin, Matthew Cannon, Larry Beaver, Virginia M. Goettl, David M. Lucas, Jennifer A. Woyach, Deepa Sampath, Amy M. Lehman, Lianbo Yu, Jiazhong Zhang, Yan Ma, Ying Zhang, Wayne Spevak, Songyuan Shi, Paul Severson, Rafe Shellooe, Heidi Carias, Garson Tsang, Ken Dong, Todd Ewing, Adhirai Marimuthu, Christina Tantoy, Jason Walters, Laura Sanftner, Hamid Rezaei, Marika Nespi, Bernice Matusow, Gaston Habets, Prabha Ibrahim, Chao Zhang, Ewy A. Mathé, Gideon Bollag, John C. Byrd & Rosa Lapalombella. (2018) BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discovery 8:4, pages 458-477.
Crossref
Christopher Chu, Eric W. Rudnick & Kiran Motaparthi. (2018) Blastic plasmacytoid dendritic cell neoplasm with centrocyte-like morphology clinically simulating a melanocytic nevus. Journal of Cutaneous Pathology 45:4, pages 249-253.
Crossref
Noelia Luna-Peláez & Mario García-Domínguez. (2018) Lyar-Mediated Recruitment of Brd2 to the Chromatin Attenuates Nanog Downregulation Following Induction of Differentiation. Journal of Molecular Biology 430:8, pages 1084-1097.
Crossref
Deepa Rajagopalan & Sudhakar Jha. (2018) An epi(c)genetic war: Pathogens, cancer and human genome. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1869:2, pages 333-345.
Crossref
Jennifer M. Sahni & Ruth A. Keri. (2018) Targeting bromodomain and extraterminal proteins in breast cancer. Pharmacological Research 129, pages 156-176.
Crossref
Richard L. BennettJonathan D. Licht. (2018) Targeting Epigenetics in Cancer. Annual Review of Pharmacology and Toxicology 58:1, pages 187-207.
Crossref
Limei Wang, Xiuyin Wu, Ruolin Wang, Chengzhe Yang, Zhi Li, Cunwei Wang, Fenghe Zhang & Pishan Yang. (2017) BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma. Biological Research 50:1.
Crossref
Yaqin Zhang, Weijie Dong, Junying Zhu, Lizhu Wang, Xinjian Wu & Hong Shan. (2017) Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell & Bioscience 7:1.
Crossref
Zhenqian Wu, Zedong Hu, Xiaodong Han, Zhongnan Li, Qingchao Zhu, Yu Wang, Qi Zheng & Jun Yan. (2017) The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression. Biomedicine & Pharmacotherapy 95, pages 1574-1579.
Crossref
Nicola Festuccia, Inma Gonzalez, Nick Owens & Pablo Navarro. (2017) Mitotic bookmarking in development and stem cells. Development 144:20, pages 3633-3645.
Crossref
Yonghui Wang, Yana Sui, Qinwei Zhu & Xiaomei Sui. (2017) Hsa-miR-599 suppresses the migration and invasion by targeting BRD4 in breast cancer. Oncology Letters 14:3, pages 3455-3462.
Crossref
Jiahuan Chen, Yi Fu, Daniel S. Day, Ye Sun, Shiyan Wang, Xiaodong Liang, Fei Gu, Fang Zhang, Sean M. Stevens, Pingzhu Zhou, Kai Li, Yan Zhang, Ruei-zeng Lin, Lois E. H. Smith, Jin Zhang, Kun Sun, Juan M. Melero-Martin, Zeguang Han, Peter J. Park, Bing Zhang & William T. Pu. (2017) VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis. Nature Communications 8:1.
Crossref
D.B. Doroshow, J.P. Eder & P.M. LoRusso. (2017) BET inhibitors: a novel epigenetic approach. Annals of Oncology 28:8, pages 1776-1787.
Crossref
Thomas C. Roberts, Usue Etxaniz, Alessandra Dall’Agnese, Shwu-Yuan Wu, Cheng-Ming Chiang, Paul E. Brennan, Matthew J. A. Wood & Pier Lorenzo Puri. (2017) BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis. Scientific Reports 7:1.
Crossref
Liping Han, Qingwei Zhao, Xianhong Liang, Xiaoqing Wang, Zhen Zhang, Zhiguo Ma, Miaoqing Zhao, Aihua Wang & Shuai Liu. (2017) Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells. Oncotarget 8:28, pages 45643-45655.
Crossref
Ranran Wang, Xing-Jun CaoKatarzyna KulejWei LiuTongcui MaMargo MacDonaldCheng-Ming Chiang, Benjamin A. GarciaJianxin You. (2017) Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. Proceedings of the National Academy of Sciences 114:27.
Crossref
Seika Amemiya, Takao Yamaguchi, Yuichi Hashimoto & Tomomi Noguchi-Yachide. (2017) Synthesis and evaluation of novel dual BRD4/HDAC inhibitors. Bioorganic & Medicinal Chemistry 25:14, pages 3677-3684.
Crossref
John E. Brogie & David H. Price. (2017) Reconstitution of a functional 7SK snRNP. Nucleic Acids Research 45:11, pages 6864-6880.
Crossref
Zhiqing Liu, Pingyuan Wang, Haiying Chen, Eric A. Wold, Bing Tian, Allan R. Brasier & Jia Zhou. (2017) Drug Discovery Targeting Bromodomain-Containing Protein 4. Journal of Medicinal Chemistry 60:11, pages 4533-4558.
Crossref
K E Lines, M Stevenson, P Filippakopoulos, S Müller, H E Lockstone, B Wright, S Grozinsky-Glasberg, A B Grossman, S Knapp, D Buck, C Bountra & R V Thakker. (2017) Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors. Oncogenesis 6:5, pages e332-e332.
Crossref
Candace J. Poole & Jan van Riggelen. (2017) MYC—Master Regulator of the Cancer Epigenome and Transcriptome. Genes 8:5, pages 142.
Crossref
Ana S. Leal, Charlotte R. Williams, Darlene B. Royce, Patricia A. Pioli, Michael B. Sporn & Karen T. Liby. (2017) Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Letters 394, pages 76-87.
Crossref
Zhongya Sun, Hao Zhang, Zhifeng Chen, Yiqian Xie, Hao Jiang, Limin Chen, Hong Ding, Yuanyuan Zhang, Hualiang Jiang, Mingyue Zheng & Cheng Luo. (2017) Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays. Bioorganic & Medicinal Chemistry Letters 27:9, pages 2003-2009.
Crossref
Irene Jiménez, André Baruchel, François Doz & Johannes Schulte. (2017) Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature. Pediatric Blood & Cancer 64:5, pages e26334.
Crossref
Jake Shortt, Christopher J. Ott, Ricky W. Johnstone & James E. Bradner. (2017) A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer 17:3, pages 160-183.
Crossref
Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira & Jaffer A. Ajani. (2016) Global chemotherapy development for gastric cancer. Gastric Cancer 20:S1, pages 92-101.
Crossref
Beatriz Suarez-Alvarez, José Luis Morgado-Pascual, Sandra Rayego-Mateos, Ramon M. RodriguezRaul Rodrigues-DiezPablo Cannata-OrtizAna B. SanzJesus Egido, Pierre-Louis Tharaux, Alberto OrtizCarlos Lopez-LarreaMarta Ruiz-Ortega. (2017) Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. Journal of the American Society of Nephrology 28:2, pages 504-519.
Crossref
Encar García-Oliver, Claire Ramus, Jonathan Perot, Marie Arlotto, Morgane Champleboux, Flore Mietton, Christophe Battail, Anne Boland, Jean-François Deleuze, Myriam Ferro, Yohann Couté & Jérôme Govin. (2017) Bdf1 Bromodomains Are Essential for Meiosis and the Expression of Meiotic-Specific Genes. PLOS Genetics 13:1, pages e1006541.
Crossref
Sara Sdelci & Stefan Kubicek. (2017) Generation of a Cellular Reporter for Functional BRD4 Inhibition. BIO-PROTOCOL 7:13.
Crossref
Zhifeng Chen, Hao Zhang, Shien Liu, Yiqian Xie, Hao Jiang, Wenchao Lu, Heng Xu, Liyan Yue, Yuanyuan Zhang, Hong Ding, Mingyue Zheng, Kunqian Yu, Kaixian Chen, Hualiang Jiang & Cheng Luo. (2017) Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay. MedChemComm 8:6, pages 1322-1331.
Crossref
Nikolas Ferreira dos Santos Paparidis, Maxwell Castro Durvale & Fernanda Canduri. (2017) The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE. Molecular BioSystems 13:2, pages 246-276.
Crossref
P.M. Woster. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 297 328 .
Arthur ZimmermannArthur Zimmermann. 2017. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 1309 1328 .
Ramiro Vázquez, Simonetta Andrea Licandro, Lucile Astorgues-Xerri, Emanuele Lettera, Nicolò Panini, Michela Romano, Eugenio Erba, Paolo Ubezio, Ezia Bello, Roberta Libener, Sara Orecchia, Federica Grosso, María Eugenia Riveiro, Esteban Cvitkovic, Mohamed Bekradda, Maurizio D'Incalci & Roberta Frapolli. (2017) Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts . International Journal of Cancer 140:1, pages 197-207.
Crossref
Saeed Alghamdi, Irfan Khan, Naimisha Beeravolu, Christina McKee, Bryan Thibodeau, George Wilson & G. Rasul Chaudhry. (2016) BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Stem Cell Research & Therapy 7:1.
Crossref
Inês Graça, Eva Pereira-Silva, Rui Henrique, Graham Packham, Simon J. Crabb & Carmen Jerónimo. (2016) Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics 8:1.
Crossref
Michelle Gonzales-Cope, Simone Sidoli, Natarajan V. Bhanu, Kyoung-Jae Won & Benjamin A. Garcia. (2016) Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells. BMC Genomics 17:1.
Crossref
Ballachanda N Devaiah, Anne Gegonne & Dinah S Singer. (2016) Bromodomain 4: a cellular Swiss army knife. Journal of Leukocyte Biology 100:4, pages 679-686.
Crossref
Simon J. Hogg, Andrea Newbold, Stephin J. Vervoort, Leonie A. Cluse, Benjamin P. Martin, Gareth P. Gregory, Marcus Lefebure, Eva Vidacs, Richard W. Tothill, James E. Bradner, Jake Shortt & Ricky W. Johnstone. (2016) BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics 15:9, pages 2030-2041.
Crossref
Ines J. de Castro, Ezgi Gokhan & Paola Vagnarelli. (2016) Resetting a functional G1 nucleus after mitosis. Chromosoma 125:4, pages 607-619.
Crossref
Caixia Wang, Heyu Chen, Mingchao Zhang, Jie Zhang, Xunbin Wei & Weihai Ying. (2016) Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis. Cancer Letters 378:1, pages 1-7.
Crossref
Goro Sashida, Changshan Wang, Takahisa Tomioka, Motohiko Oshima, Kazumasa Aoyama, Akinori Kanai, Makiko Mochizuki-Kashio, Hironori Harada, Kazuya Shimoda & Atsushi Iwama. (2016) The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. Journal of Experimental Medicine 213:8, pages 1459-1477.
Crossref
Laura Lori, Alessandra Pasquo, Clorinda Lori, Maria Petrosino, Roberta Chiaraluce, Cynthia Tallant, Stefan Knapp & Valerio Consalvi. (2016) Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability. PLOS ONE 11:7, pages e0159180.
Crossref
Sara Sdelci, Charles-Hugues Lardeau, Cynthia Tallant, Freya Klepsch, Björn Klaiber, James Bennett, Philipp Rathert, Michael Schuster, Thomas Penz, Oleg Fedorov, Giulio Superti-Furga, Christoph Bock, Johannes Zuber, Kilian V M Huber, Stefan Knapp, Susanne Müller & Stefan Kubicek. (2016) Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nature Chemical Biology 12:7, pages 504-510.
Crossref
Chris C.-S. Hsiung, Caroline R. Bartman, Peng Huang, Paul Ginart, Aaron J. Stonestrom, Cheryl A. Keller, Carolyne Face, Kristen S. Jahn, Perry Evans, Laavanya Sankaranarayanan, Belinda Giardine, Ross C. Hardison, Arjun Raj & Gerd A. Blobel. (2016) A hyperactive transcriptional state marks genome reactivation at the mitosis–G1 transition. Genes & Development 30:12, pages 1423-1439.
Crossref
Jennifer Varin, Laury Poulain, Mikael Hivelin, Patrick Nusbaum, Arnaud Hubas, Ingrid Laurendeau, Laurent Lantieri, Pierre Wolkenstein, Michel Vidaud, Eric Pasmant, Nicolas Chapuis & Béatrice Parfait. (2016) Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget 7:24, pages 35753-35767.
Crossref
Balasundaram Padmanabhan, Shruti Mathur, Ramu Manjula & Shailesh Tripathi. (2016) Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases. Journal of Biosciences 41:2, pages 295-311.
Crossref
Seong Hwi Hong, Jung Woo Eun, Sung Kyung Choi, Qingyu Shen, Wahn Soo Choi, Jeung-Whan Han, Suk Woo Nam & Jueng Soo You. (2016) Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer. Oncotarget 7:22, pages 32628-32640.
Crossref
Anton Henssen, Kristina Althoff, Andrea Odersky, Anneleen Beckers, Richard Koche, Frank Speleman, Simon Schäfers, Emma Bell, Maike Nortmeyer, Frank Westermann, Katleen De Preter, Alexandra Florin, Lukas Heukamp, Annika Spruessel, Kathy Astrahanseff, Sven Lindner, Natalie Sadowski, Alexander Schramm, Lucile Astorgues-Xerri, Maria E. Riveiro, Angelika Eggert, Esteban Cvitkovic & Johannes H. Schulte. (2016) Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clinical Cancer Research 22:10, pages 2470-2481.
Crossref
Camille Jacques, François Lamoureux, Marc Baud’huin, Lidia Rodriguez Calleja, Thibaut Quillard, Jérôme Amiaud, Franck Tirode, Françoise Rédini, James E. Bradner, Dominique Heymann & Benjamin Ory. (2016) Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget 7:17, pages 24125-24140.
Crossref
Reza K. Oqani, Tao Lin, Jae Eun Lee, Ki Myung Choi, Hyun Young Shin & Dong Il Jin. (2016) P-TEFb Kinase Activity Is Essential for Global Transcription, Resumption of Meiosis and Embryonic Genome Activation in Pig. PLOS ONE 11:3, pages e0152254.
Crossref
Aaron J. Stonestrom, Sarah C. Hsu, Michael T. Werner & Gerd A. Blobel. (2016) Erythropoiesis provides a BRD's eye view of BET protein function. Drug Discovery Today: Technologies 19, pages 23-28.
Crossref
Brian K. Albrecht, Victor S. Gehling, Michael C. Hewitt, Rishi G. Vaswani, Alexandre Côté, Yves Leblanc, Christopher G. Nasveschuk, Steve Bellon, Louise Bergeron, Robert Campbell, Nico Cantone, Michael R. Cooper, Richard T. Cummings, Hariharan Jayaram, Shivangi Joshi, Jennifer A. Mertz, Adrianne Neiss, Emmanuel Normant, Michael O’Meara, Eneida Pardo, Florence Poy, Peter Sandy, Jeffrey Supko, Robert J. SimsIIIIII, Jean-Christophe Harmange, Alexander M. Taylor & James E. Audia. (2016) Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. Journal of Medicinal Chemistry 59:4, pages 1330-1339.
Crossref
Yun-Fei Liao, Yong-Bing Wu, Xiang Long, Shu-Qiang Zhu, Chun Jin, Jian-Jun Xu & Jian-Yong Ding. (2016) High level of BRD4 promotes non-small cell lung cancer progression. Oncotarget 7:8, pages 9491-9500.
Crossref
Nicholas J. Kuypers, Andrew N. Bankston, Russell M. Howard, Jason E. Beare & Scott R. Whittemore. (2016) Remyelinating Oligodendrocyte Precursor Cell miRNAs from the Sfmbt2 Cluster Promote Cell Cycle Arrest and Differentiation. The Journal of Neuroscience 36:5, pages 1698-1710.
Crossref
Tomomi Noguchi-Yachide. (2016) BET Bromodomain as a Target of Epigenetic Therapy. CHEMICAL & PHARMACEUTICAL BULLETIN Chemical and Pharmaceutical Bulletin 64:6, pages 540-547.
Crossref
Xuemei Gao, Xinchao Wu, Xiao Zhang, Wenjuan Hua, Yajing Zhang, Yusufu Maimaiti, Zairong Gao & Yongxue Zhang. (2016) Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochemical and Biophysical Research Communications 469:3, pages 679-685.
Crossref
Panagis Filippakopoulos & Stefan Knapp. 2016. Drug Discovery in Cancer Epigenetics. Drug Discovery in Cancer Epigenetics 239 271 .
Filipa Quintela Vieira, Diogo Almeida-Rios, Inês Graça, Rui Henrique & Carmen Jerónimo. 2016. Epigenetic Biomarkers and Diagnostics. Epigenetic Biomarkers and Diagnostics 447 465 .
Arthur ZimmermannArthur Zimmermann. 2016. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 1 20 .
Alexander Harms, Esther Herpel, Nicole Pfarr, Roland Penzel, Claus-Peter Heussel, Felix J.F. Herth, Hendrik Dienemann, Wilko Weichert & Arne Warth. (2015) NUT carcinoma of the thorax: Case report and review of the literature. Lung Cancer 90:3, pages 484-491.
Crossref
YONG-HUI WANG, XIAO-MEI SUI, YA-NA SUI, QIN-WEI ZHU, KAI YAN, LI-SHAN WANG, FEI WANG & JIA-HUA ZHOU. (2015) BRD4 induces cell migration and invasion in HCC cells through MMP-2 and MMP-9 activation mediated by the Sonic hedgehog signaling pathway. Oncology Letters 10:4, pages 2227-2232.
Crossref
Ryan Lenhart, Stefan Kirov, Heshani Desilva, Jian Cao, Ming Lei, Kathy Johnston, Russell Peterson, Liang Schweizer, Ashok Purandare, Petra Ross-Macdonald, Craig Fairchild, Tai Wong & Susan Wee. (2015) Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression . Molecular Cancer Therapeutics 14:10, pages 2167-2174.
Crossref
Hai-Jing Zhong, Lihua Lu, Ka-Ho Leung, Catherine C. L. Wong, Chao Peng, Siu-Cheong Yan, Dik-Lung Ma, Zongwei Cai, Hui-Min David Wang & Chung-Hang Leung. (2015) An iridium( iii )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent . Chemical Science 6:10, pages 5400-5408.
Crossref
Zane Zeier, Rustam Esanov, Kinsley C. Belle, Claude-Henry Volmar, Andrea L. Johnstone, Paul Halley, Brooke A. DeRosa, Nathalie Khoury, Marka van Blitterswijk, Rosa Rademakers, Jeffrey Albert, Shaun P. Brothers, Joanne Wuu, Derek M. Dykxhoorn, Michael Benatar & Claes Wahlestedt. (2015) Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology 271, pages 241-250.
Crossref
Minoru Tanaka, Justin M Roberts, Jun Qi & James E Bradner. (2015) Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010–2014). Pharmaceutical Patent Analyst 4:4, pages 261-284.
Crossref
Huasong Lu, Yuhua Xue, Guoying K Yu, Carolina Arias, Julie Lin, Susan Fong, Michel Faure, Ben Weisburd, Xiaodan Ji, Alexandre Mercier, James Sutton, Kunxin Luo, Zhenhai Gao & Qiang Zhou. (2015) Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. eLife 4.
Crossref
Marie Jung, Kathy A Gelato, Amaury Fernández-Montalván, Stephan Siegel & Bernard Haendler. (2015) Targeting BET bromodomains for cancer treatment. Epigenomics 7:3, pages 487-501.
Crossref
Aristeidis Chaidos, Valentina Caputo & Anastasios Karadimitris. (2015) Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Therapeutic Advances in Hematology 6:3, pages 128-141.
Crossref
K Althoff, A Beckers, E Bell, M Nortmeyer, T Thor, A Sprüssel, S Lindner, K De Preter, A Florin, L C Heukamp, L Klein-Hitpass, K Astrahantseff, C Kumps, F Speleman, A Eggert, F Westermann, A Schramm & J H Schulte. (2014) A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 34:26, pages 3357-3368.
Crossref
Michael C. Hewitt, Yves Leblanc, Victor S. Gehling, Rishi G. Vaswani, Alexandre Côté, Christopher G. Nasveschuk, Alexander M. Taylor, Jean-Christophe Harmange, James E. Audia, Eneida Pardo, Rich Cummings, Shivangi Joshi, Peter Sandy, Jennifer A. Mertz, Robert J. SimsIIIIII, Louise Bergeron, Barbara M. Bryant, Steve Bellon, Florence Poy, Hariharan Jayaram, Yong Tang & Brian K. Albrecht. (2015) Development of methyl isoxazoleazepines as inhibitors of BET. Bioorganic & Medicinal Chemistry Letters 25:9, pages 1842-1848.
Crossref
Steven Fletcher & Edward V. Prochownik. (2015) Small-molecule inhibitors of the Myc oncoprotein. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1849:5, pages 525-543.
Crossref
Dhong Hyun Lee, Jun Qi, James E. Bradner, Jonathan W. Said, Ngan B. Doan, Charles Forscher, Henry Yang & H. Phillip Koeffler. (2015) Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. International Journal of Cancer 136:9, pages 2055-2064.
Crossref
YONG-HUI WANG, YA-NA SUI, KAI YAN, LI-SHAN WANG, FEI WANG & JIA-HUA ZHOU. (2015) BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Oncology Reports 33:4, pages 1699-1706.
Crossref
Pengfei Zhang, Zhaoru Dong, Jiabin Cai, Chi Zhang, Zaozhuo Shen, Aiwu Ke, Dongmei Gao, Jia Fan & Guoming Shi. (2015) BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology 28:1, pages 36-44.
Crossref
Tao Wu, Hugo Borges Pinto, Yasunao F. Kamikawa & Mary E. Donohoe. (2015) The BET Family Member BRD4 Interacts with OCT4 and Regulates Pluripotency Gene Expression. Stem Cell Reports 4:3, pages 390-403.
Crossref
Tomomi Noguchi-Yachide, Taki Sakai, Yuichi Hashimoto & Takao Yamaguchi. (2015) Discovery and structure–activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors. Bioorganic & Medicinal Chemistry 23:5, pages 953-959.
Crossref
Chris C.-S. Hsiung, Christapher S. Morrissey, Maheshi Udugama, Christopher L. Frank, Cheryl A. Keller, Songjoon Baek, Belinda Giardine, Gregory E. Crawford, Myong-Hee Sung, Ross C. Hardison & Gerd A. Blobel. (2015) Genome accessibility is widely preserved and locally modulated during mitosis. Genome Research 25:2, pages 213-225.
Crossref
Yuan Hu, Jieqiong Zhou, Fei Ye, Huabao Xiong, Liang Peng, Zihan Zheng, Feihong Xu, Miao Cui, Chengguo Wei, Xinying Wang, Zhongqiu Wang, Hongfa Zhu, Peng Lee, Mingming Zhou, Bo Jiang & David Zhang. (2015) BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis. International Journal of Molecular Sciences 16:1, pages 1928-1948.
Crossref
Ranran Wang & Jianxin You. (2015) Mechanistic Analysis of the Role of Bromodomain-containing Protein 4 (BRD4) in BRD4-NUT Oncoprotein-induced Transcriptional Activation. Journal of Biological Chemistry 290:5, pages 2744-2758.
Crossref
Antonia Masch, Ulf Reimer, Johannes Zerweck & Mike Schutkowski. 2015. Epigenetic Technological Applications. Epigenetic Technological Applications 169 186 .
David S. Hewings, Timothy P.C. Rooney & Stuart J. Conway. 2015. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy 495 524 .
Szu-Wei Chang, Wei-Chen Liu, Kuan-Yu Liao, Yeou-Ping Tsao, Pang-Hung Hsu & Show-Li Chen. (2014) Phosphorylation of HPV-16 E2 at Serine 243 Enables Binding to Brd4 and Mitotic Chromosomes. PLoS ONE 9:10, pages e110882.
Crossref
Jessica E. Bolden, Nilgun Tasdemir, Lukas E. Dow, Johan H. van Es, John E. Wilkinson, Zhen Zhao, Hans Clevers & Scott W. Lowe. (2014) Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition. Cell Reports 8:6, pages 1919-1929.
Crossref
Xiangming Hu, Xiaodong Lu, Runzhong Liu, Nanping Ai, Zhenhua Cao, Yannan Li, Jiangfang Liu, Bin Yu, Kai Liu, Huiping Wang, Chao Zhou, Yu Wang, Aidong Han, Feng Ding & Ruichuan Chen. (2014) Histone Cross-talk Connects Protein Phosphatase 1α (PP1α) and Histone Deacetylase (HDAC) Pathways to Regulate the Functional Transition of Bromodomain-containing 4 (BRD4) for Inducible Gene Expression. Journal of Biological Chemistry 289:33, pages 23154-23167.
Crossref
Xiaodan Ji, Huasong Lu, Qiang Zhou & Kunxin Luo. (2014) LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. eLife 3.
Crossref
Junwei Shi & Christopher R. Vakoc. (2014) The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. Molecular Cell 54:5, pages 728-736.
Crossref
Charalambos Michaeloudes, Nicolas Mercado, Colin Clarke, Pankaj K. Bhavsar, Ian M. Adcock, Peter J. Barnes & Kian Fan Chung. (2014) Bromodomain and Extraterminal Proteins Suppress NF-E2–Related Factor 2–Mediated Antioxidant Gene Expression. The Journal of Immunology 192:10, pages 4913-4920.
Crossref
Caroline P. Passaes & Asier Sáez-Cirión. (2014) HIV cure research: Advances and prospects. Virology 454-455, pages 340-352.
Crossref
Reza K. Oqani, Jung Won Kang, Tao Lin, Jae Eun Lee & Dong-Il Jin. (2014) General Transcription Factors and Embryonic Genome Activation. Reproductive & developmental Biology 38:1, pages 41-52.
Crossref
Marie Jung, Martin Philpott, Susanne Müller, Jessica Schulze, Volker Badock, Uwe Eberspächer, Dieter Moosmayer, Benjamin Bader, Norbert Schmees, Amaury Fernández-Montalván & Bernard Haendler. (2014) Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1. Journal of Biological Chemistry 289:13, pages 9304-9319.
Crossref
S. Müller & S. Knapp. (2014) Discovery of BET bromodomain inhibitors and their role in target validation. MedChemComm 5:3, pages 288-296.
Crossref
Jing Li, Qing Li, Jason Diaz & Jianxin You. (2014) Brd4-Mediated Nuclear Retention of the Papillomavirus E2 Protein Contributes to Its Stabilization in Host Cells. Viruses 6:1, pages 319-335.
Crossref
Lingyan Jin, Weiru WangGuowei Fang. (2014) Targeting Protein-Protein Interaction by Small Molecules. Annual Review of Pharmacology and Toxicology 54:1, pages 435-456.
Crossref
Ruichuan Chen, Jasper H. N. Yik, Qiao Jing Lew & Sheng-Hao Chao. (2014) Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer. BioMed Research International 2014, pages 1-11.
Crossref
Amish J. Patel, Chung-Ping Liao, Zhiguo Chen, Chiachi Liu, Yong Wang & Lu Q. Le. (2014) BET Bromodomain Inhibition Triggers Apoptosis of NF1-Associated Malignant Peripheral Nerve Sheath Tumors through Bim Induction. Cell Reports 6:1, pages 81-92.
Crossref
Stephan Kadauke & Gerd A Blobel. (2013) Mitotic bookmarking by transcription factors. Epigenetics & Chromatin 6:1.
Crossref
Wen Liu, Qi Ma, Kaki Wong, Wenbo Li, Kenny Ohgi, Jie Zhang, Aneel K. Aggarwal & Michael G. Rosenfeld. (2013) Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release. Cell 155:7, pages 1581-1595.
Crossref
Bjoern Chapuy, Michael R. McKeown, Charles Y. Lin, Stefano Monti, Margaretha G.M. Roemer, Jun Qi, Peter B. Rahl, Heather H. Sun, Kelly T. Yeda, John G. Doench, Elaine Reichert, Andrew L. Kung, Scott J. Rodig, Richard A. Young, Margaret A. Shipp & James E. Bradner. (2013) Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell 24:6, pages 777-790.
Crossref
Anton Henssen, Theresa Thor, Andrea Odersky, Lukas Heukamp, Nicolai El-Hindy, Anneleen Beckers, Frank Speleman, Kristina Althoff, Simon Schäfers, Alexander Schramm, Ulrich Sure, Gudrun Fleischhack, Angelika Eggert & Johannes H. Schulte. (2013) BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4:11, pages 2080-2095.
Crossref

Displaying 200 of 263 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.